Cyano Biotech GmbH

Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health.

Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

At Aragen, we recognize your work is vital, urgent and impacts lives. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.

Established in 1951, Fermenta Biotech Limited (FBL) is one of the largest manufacturers of Vitamin D3 and a key global player. Headquartered in Thane, India, FBL caters to clientele across the globe, with a worldwide distribution network. Its state-of-the-art R&D centre is based at Thane, and world class manufacturing facilities are located in Kullu, Himachal Pradesh and Dahej, Gujarat. Apart from Vitamin D3, FBL also offers niche APIs, integrated biotechnology platforms such as enzymes for antibiotic synthesis as well as environmental solutions for waste water management and treatment.

Established in 1951, Fermenta Biotech Limited (FBL) is one of the largest manufacturers of Vitamin D3 and a key global player. Headquartered in Thane, India, FBL caters to clientele across the globe, with a worldwide distribution network. Its state-of-the-art R&D centre is based at Thane, and world class manufacturing facilities are located in Kullu, Himachal Pradesh and Dahej, Gujarat. Apart from Vitamin D3, FBL also offers niche APIs, integrated biotechnology platforms such as enzymes for antibiotic synthesis as well as environmental solutions for waste water management and treatment.

Aragen is a trusted R&D and manufacturing partner to the global life sciences industry. From concept to commercial, we transform your ideas into solutions for better health.

Whether large pharma or biotech, an agrochemical or animal health company, we provide you global resources and proven capabilities at every stage of the biopharma lifecycle, in small and large molecules. Our ability to offer end-to-end solutions or support standalone programs is underpinned by an innovation mindset, enabling technologies, and a partnership approach to every engagement.

At Aragen, we recognize your work is vital, urgent and impacts lives. Our purpose, ‘In every molecule is the possibility for better health’ motivates us to drive the success of your programs, so that we can together transform hope into health for millions of people around the world.

Kemwell is a contract biologics development and CMO company providing services to global biopharmaceutical organizations. Kemwell facilities, located in Bangalore, India, are designed and developed with technological support from a leading German pharma company. Kemwell provides customers with cost-effective access to state-of-the-art technology for all mammalian cell culture based products’ development and manufacturing.

15,000 sq. m. Kemwell facility consists of a cGMP drug substance manufacturing area with over 4500L bioreactor capacity, sterile fill and finish areas for cGMP drug product manufacturing and process development laboratories to support production of protein therapeutics from mammalian-cell culture – monoclonal antibodies, bi-specific antibodies, fusion proteins, etc. Kemwell is capable of supporting novel, bio-better and biosimilar programs’ preclinical development, clinical development, cGMP clinical manufacturing and cGMP commercial manufacturing.

Kemwell, having established in 1980, had long term associations with pharma majors such as Bayer, GlaxoSmithKline, Merck KGaA, Novartis, Pfizer and others for small molecule contract mfg. and R&D. In 2016, Kemwell divested its small-molecule division to focus on biologics, leveraging its vast and rich experience. Kemwell is now a 100% biologics CDMO.